DZ2873A1 - Procédé pour augmenter la dureté et la rigidité osseuse. - Google Patents

Procédé pour augmenter la dureté et la rigidité osseuse.

Info

Publication number
DZ2873A1
DZ2873A1 DZ990173A DZ990173A DZ2873A1 DZ 2873 A1 DZ2873 A1 DZ 2873A1 DZ 990173 A DZ990173 A DZ 990173A DZ 990173 A DZ990173 A DZ 990173A DZ 2873 A1 DZ2873 A1 DZ 2873A1
Authority
DZ
Algeria
Prior art keywords
stiffness
increasing bone
bone hardness
hardness
increasing
Prior art date
Application number
DZ990173A
Other languages
English (en)
French (fr)
Inventor
Janet M Hock
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2873(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DZ2873A1 publication Critical patent/DZ2873A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
DZ990173A 1998-08-19 1999-08-18 Procédé pour augmenter la dureté et la rigidité osseuse. DZ2873A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
DZ2873A1 true DZ2873A1 (fr) 2003-12-15

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990173A DZ2873A1 (fr) 1998-08-19 1999-08-18 Procédé pour augmenter la dureté et la rigidité osseuse.

Country Status (32)

Country Link
US (2) US6977077B1 (enExample)
EP (3) EP2907522B1 (enExample)
JP (5) JP2002523375A (enExample)
KR (1) KR100454207B1 (enExample)
CN (1) CN1205997C (enExample)
AR (1) AR033639A1 (enExample)
AT (1) ATE231000T1 (enExample)
AU (1) AU746277B2 (enExample)
BR (1) BR9909445A (enExample)
CA (1) CA2325371C (enExample)
CO (1) CO5130020A1 (enExample)
CY (2) CY1113343T1 (enExample)
CZ (1) CZ301017B6 (enExample)
DE (2) DE15152726T1 (enExample)
DK (4) DK1059933T3 (enExample)
DZ (1) DZ2873A1 (enExample)
EA (1) EA003362B1 (enExample)
ES (4) ES2549551T3 (enExample)
HR (1) HRP20000755A2 (enExample)
HU (2) HU230697B1 (enExample)
ID (1) ID29039A (enExample)
IL (2) IL138829A0 (enExample)
MY (1) MY129227A (enExample)
NO (2) NO323984B1 (enExample)
NZ (1) NZ507056A (enExample)
PE (1) PE20001089A1 (enExample)
PL (1) PL201688B1 (enExample)
PT (4) PT2266598T (enExample)
TR (1) TR200003455T2 (enExample)
TW (1) TW576747B (enExample)
UA (1) UA72205C2 (enExample)
WO (1) WO2000010596A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
WO2003059291A2 (en) * 2002-01-10 2003-07-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
WO2005027915A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
JP5007427B2 (ja) 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
EP1879608A4 (en) * 2005-05-11 2009-11-11 Unigene Lab Inc METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
BRPI0618469A2 (pt) * 2005-11-10 2011-08-30 Univ Michigan Tech hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
EP2136850B1 (en) 2007-04-13 2012-02-01 Kuros Biosurgery AG Polymeric tissue sealant
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
EP2217260B1 (en) * 2007-12-04 2016-11-09 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
JP2012512812A (ja) 2007-12-28 2012-06-07 クロス・バイオサージェリー・アクチェンゲゼルシャフト フィブリンフォームに組込まれたｐｄｇｆ融合タンパク質
CN103893746A (zh) * 2009-09-09 2014-07-02 旭化成制药株式会社 含有pth的骨质疏松症治疗/预防剂
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
KR101787956B1 (ko) 2011-06-07 2017-10-18 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3411066B1 (en) * 2016-02-01 2026-05-13 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
WO2018144719A1 (en) * 2017-02-01 2018-08-09 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
CA3101326C (en) 2018-10-29 2023-08-01 Asahi Kasei Pharma Corporation Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week
EP4010360A1 (en) 2019-08-09 2022-06-15 Flagship Pioneering Innovations VI, LLC Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
US5747456A (en) 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
PT806945E (pt) * 1994-12-22 2003-09-30 Astrazeneca Ab Preparacao terapeutica para inalacao que contem a hormona paratiroide, hpt
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
CA2302255C (en) * 1997-09-09 2011-11-08 F. Hoffmann-La Roche Ag Fracture healing using pthrp analogs
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
JP2011021035A (ja) 2011-02-03
EP1059933B1 (en) 2003-01-15
NO323984B1 (no) 2007-07-30
HUP0101594A3 (en) 2002-01-28
ES2549551T1 (es) 2015-10-29
IL138829A (en) 2011-01-31
IL138829A0 (en) 2001-10-31
HUP0101594A2 (hu) 2001-11-28
AU746277B2 (en) 2002-04-18
US7163684B2 (en) 2007-01-16
ES2549551T3 (es) 2017-11-27
CO5130020A1 (es) 2002-02-27
EP2266598A1 (en) 2010-12-29
PT2266598T (pt) 2017-05-02
ES2621653T3 (es) 2017-07-04
PL201688B1 (pl) 2009-04-30
JP2002523375A (ja) 2002-07-30
NO20005947D0 (no) 2000-11-24
AU5575099A (en) 2000-03-14
CA2325371C (en) 2004-08-17
DE69904918D1 (de) 2003-02-20
CZ301017B6 (cs) 2009-10-14
DK1059933T3 (da) 2003-04-07
PL343595A1 (en) 2001-08-27
CY1119552T1 (el) 2018-03-07
US6977077B1 (en) 2005-12-20
HRP20000755A2 (en) 2001-02-28
JP2015028065A (ja) 2015-02-12
DK1769804T3 (da) 2012-10-15
EA200001015A1 (ru) 2001-02-26
ES2393200T3 (es) 2012-12-19
JP6177718B2 (ja) 2017-08-09
HU1200430D0 (hu) 2001-11-28
TR200003455T2 (tr) 2001-06-21
NZ507056A (en) 2003-10-31
WO2000010596A1 (en) 2000-03-02
US20050197294A1 (en) 2005-09-08
HK1102496A1 (en) 2007-11-23
BR9909445A (pt) 2000-12-12
EP2266598B1 (en) 2017-02-22
ES2190244T3 (es) 2003-07-16
NO20005947L (no) 2000-11-24
JP2014139220A (ja) 2014-07-31
PT1059933E (pt) 2003-06-30
EP2907522B1 (en) 2017-08-02
PT2907522T (pt) 2017-10-23
JP2017190332A (ja) 2017-10-19
DK2907522T3 (en) 2017-10-23
HK1212602A1 (en) 2016-06-17
EP2907522A1 (en) 2015-08-19
DE15152726T1 (de) 2015-12-10
HK1030545A1 (en) 2001-05-11
TW576747B (en) 2004-02-21
CZ20004134A3 (cs) 2001-08-15
PT1769804E (pt) 2012-11-13
UA72205C2 (uk) 2005-02-15
CA2325371A1 (en) 2000-03-02
EA003362B1 (ru) 2003-04-24
CY1113343T1 (el) 2016-06-22
AR033639A1 (es) 2004-01-07
EP1059933A1 (en) 2000-12-20
DK2266598T3 (en) 2017-05-15
KR100454207B1 (ko) 2004-10-26
ID29039A (id) 2001-07-26
PE20001089A1 (es) 2000-11-04
MY129227A (en) 2007-03-30
CN1205997C (zh) 2005-06-15
KR20010072763A (ko) 2001-07-31
HU230697B1 (hu) 2017-09-28
ATE231000T1 (de) 2003-02-15
DK2907522T1 (da) 2015-10-19
CN1308545A (zh) 2001-08-15
DE69904918T2 (de) 2003-11-13
NO20072983L (no) 2000-11-24

Similar Documents

Publication Publication Date Title
IL138829A0 (en) Method for increasing bone toughness and stiffness and reducing fractures
BR9803500B1 (pt) método e aparelho para tratamento de refugo.
EP1156324A4 (en) PROCESS FOR THE DISTINCTION OF SAMPLES
NO20011084L (no) Presisjonstidsstyrende generatorsystem og fremgangsmåte.
EP1103812A4 (en) METHOD FOR DETERMINING HEMOGLOBINS
DZ2851A1 (fr) Procédé d'émulsification.
ID28489A (id) Metode untuk membuat 4-karboksiamino-2-disubstitusi 1,2,3,4-tetrahidroquinolin
FR2782656B1 (fr) Distributeur-melangeur-extracteur de fluides et procede associe
PT940381E (pt) Processo para recuperacao de ciclopentano e/ou ciclopenteno
DE59906356D1 (de) Sichtscheibe für eine skibrille
FI961827L (fi) Menetelmä 1,3-diolien monoesterien valmistamiseksi
BR9800458A (pt) Processo para preparação de poliéter polióis
ATA193297A (de) Präzisionswalzverfahren
FR2720342B1 (fr) Procédé pour augmenter la motricité.
EP1113415A4 (en) METHOD FOR EXTRACING SOUND SOURCE INFORMATION
DE69929026D1 (de) Bildgebungsverfahren für bildgesteuerte chirurgie
ZA989693B (en) Method for treating disease-related or drug-induced dyskinesias
IT1298539B1 (it) Metodo per la determinazione di infezioni da protesi
DE69914560D1 (de) Verfahren zur acylierung von aminoalcoholen
FI982735L (fi) Menetelmä lietteen säilyvyyden parantamiseksi
EP1028626A4 (en) METHOD FOR INCREASING GENE EXPRESSION
PT974275E (pt) Proceso para esterilizacao
ID28452A (id) Metode untuk mengadaptasi kecepatan data
FI981087L (fi) Monilietemenetelmä lannoitteen valmistamiseksi
DE59602924D1 (de) Knochenraspel